Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. It is used together with a diabetic diet and exercise. It is not indicated for use by itself in type 1 diabetes. It is taken by mouth. Effects generally begin within half an hour and can last for up to a day. Common side effects include nausea, diarrhea, low blood sugar, and

headache Headache is the symptom of pain in the face, head, or neck. It can occur as a migraine, tension-type headache, or cluster headache. There is an increased risk of depression in those with severe headaches. Headaches can occur as a result ...

. Other side effects include sleepiness, skin rash, and shakiness. The dose may need to be adjusted in those with liver or

kidney disease Kidney disease, or renal disease, technically referred to as nephropathy, is damage to or disease of a kidney. Nephritis is an inflammatory kidney disease and has several types according to the location of the inflammation. Inflammation can ...

. Use during pregnancy or breastfeeding is not recommended. It works by stimulating the pancreas to release

insulin Insulin (, from Latin ''insula'', 'island') is a peptide hormone produced by beta cells of the pancreatic islets encoded in humans by the ''INS'' gene. It is considered to be the main anabolic hormone of the body. It regulates the metabolism o ...

and increases tissue sensitivity to insulin. Glipizide was approved for medical use in the United States in 1984. It is available as a

generic medication A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active ch ...

. In 2020, it was the 49th most commonly prescribed medication in the United States, with more than 13million prescriptions.

Mechanism of action

Glipizide sensitizes the beta cells of pancreatic islets of Langerhans insulin response, meaning that more insulin is released in response to glucose than would be without glipizide ingestion. Glipizide acts by partially blocking potassium channels among beta cells of pancreatic islets of Langerhans. By blocking potassium channels, the cell depolarizes, which results in the opening of voltage-gated calcium channels. The resulting calcium influx encourages insulin release from beta cells.

History

It was patented in 1969 and approved for medical use in 1971. Glipizide was approved for medical use in the United States in 1984.

References

External links

* {{Portal bar , Medicine Potassium channel blockers 1-(Benzenesulfonyl)-3-cyclohexylureas Pyrazines Pfizer brands Wikipedia medicine articles ready to translate